Kura Oncology (KURA)
(Delayed Data from NSDQ)
$21.76 USD
-0.30 (-1.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $21.79 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 181 - 200 ( 258 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Impressive Median Overall Survival for Tipifarnib in HRAS-HNSCC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
When You''re Better Than Prior Therapies, That Says Something
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; AIM Re-Aimed; KO-539 Development Prioritized
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; Strategic Focus for Optimized Resource Use Makes Sense to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Wedbush Monthly Check-Up: May 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Continuing to Build a Strong Precision Targeted Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Tipifarnib HNSCC Study On Track with Fast Track
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Fast Track and Increasing Visibility on AIM-HN as We Near First End-Game
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Looks Like Tipifarnib Ready for Prime Time in AITL
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
AITL Update at ASH; FDA Gives Nod to Registration-Directed Ph 2 Design
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; AIM-HN Pushes Forward and ASH Bringing Important Heme Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Update for Tipifarnib in AITL Patients Ahead at ASH
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R